Tokyo (January 14, 2003) - Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) has announced that its U.S. subsidiary, Eisai Inc. (Headquarters: New Jersey, Chairman: Soichi Matsuno), has revealed plans to strengthen its national sales force by adding 150 sales representatives this year. During a two-year period, Eisai Inc. plans to double its sales force to more than 500 sales representatives from the current 250 sales representatives.
This expansion will enable Eisai Inc. to support increasing sales of its Alzheimer's treatment, ARICEPT (donepezil hydrochloride tablets), and its proton pump inhibitor, ACIPHEX (rabeprazole sodium), and bring product information to more prescribers. It will further improve sales force geographical balance and operational cost efficiency.
Eisai Inc. possesses integrated capabilities in research and development, manufacturing, sales, promotion and distribution, and has achieved rapid growth with sales of more than $1 billion in 2001. Eisai Inc. co-promotes ARICEPT and ACIPHEX with Pfizer Inc. and Janssen Pharmaceutica respectively.